drugset / Trial / NCT03761277

Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain

NCT03761277

Phase 4 Completed 93 enrolled MedtronicNeuro
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multi-center, post market study to evaluate Intrathecal (IT) preservative-free morphine sulfate (PFMS) using the SynchroMed™ II infusion system as an alternative to systemic opioids for the treatment of chronic, intractable, non-malignant primary back pain with or without leg pain.

Timeline

Start
2019-01-16
Primary completion
2021-12-06
Completion
2021-12-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified Intrathecal